Biotech Startups

Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.

4 investors

Matrubials develops antimicrobial peptides derived from milk to create novel therapeutics for bacterial infections, starting with bacterial vaginosis. The company uses AI-enabled technology to identify and validate bioactive molecules for infectious disease treatments.

4 investors

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.

4 investors

MC10 developed conformal BioStamp wearable sensors and clinical analytics for physiological data capture in clinical research.

4 investors

Advancing gene and cell therapy delivery systems to address precision targeting challenges in living patients.

4 investors

RarePath is a biotech platform that creates pathways for scientists to develop cures for rare and ultra-rare diseases by partnering with academic researchers, biotech firms, and patient foundations to fund, license, and commercialize therapies.

4 investors

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.

4 investors

Mesentech develops prostaglandin prodrugs aimed at musculoskeletal regeneration. The company operates in the biotechnology and drug development space.

4 investors

Metabolon provides metabolomics services and bioinformatics tools that measure small molecules to give biological context to research data. It serves biopharma, public health, consumer wellness, agriculture, and academic research clients across discovery, clinical, and translational studies.

4 investors

MiAlgae uses whisky distillation by-products to grow microalgae rich in marine Omega 3s, offering a plant-based, low-carbon alternative to fish oil. The Omega 3 rich algae is dried for use in farmed fish feed and pet food.

4 investors

Micrographia Bio pairs imaging mass spectrometry with AI analysis to map how proteins are distributed across tissue samples at cellular resolution. Drug developers use the resulting spatial proteomics data to identify potential therapeutic targets and study mechanisms of action.

4 investors

MIMOSA Diagnostics develops medical devices and technology to improve healthcare equity through diagnostic solutions. The company focuses on skin and wound healing diagnostics with a team led by experienced medical device engineers and healthcare professionals.

4 investors

Minutia develops insulin-producing cell transplants that can be monitored in vivo over time, aimed at improving cell replacement therapy for diabetes. The company works in the regenerative medicine and cell therapy field.

4 investors

Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases. It focuses on developing novel therapeutics for rare diseases with high unmet clinical need.

4 investors

Miruku develops dairy proteins produced from oilseed crops, targeting the food and beverage industry. The company combines plant biotechnology with dairy science to create sustainable alternatives to traditional dairy.

4 investors

MitoRx develops first-in-class, targeted small-molecule therapies that restore mitochondrial health to treat people with high-risk, metabolically unhealthy obesity and related cardiometabolic diseases. Its lead asset, MTRX31, aims to rebalance carbohydrate and fat oxidation to deliver fat-specific weight loss while preserving lean mass.

4 investors

MOA Food Tech develops sustainable food ingredients. The company is focused on producing alternative ingredients for the food industry.

4 investors

MOBILion Systems develops the MOBIE platform, a high-resolution ion mobility mass spectrometry (HRIM-MS) instrument that separates and identifies complex molecules in separation science. It serves pharmaceutical, biopharma, academic, and diagnostics labs across cell and gene therapy, therapeutic characterization, food and environmental testing, and biomarker research.

4 investors

Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

4 investors

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.

4 investors

Mothership Materials converts industrial agricultural and food waste into non-food-competitive feedstocks for biomanufacturing, using patented modular technology deployed at waste sources to recover molecules such as sugar for precision fermentation and cellulose for fibers. It targets biomanufacturing companies seeking lower-cost inputs than conventional food supply chains.

4 investors

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX. The company is no longer operating.

4 investors

Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.

4 investors

myBiometry develops electrochemical biosensor technology for non-invasive measurement of airway inflammation biomarkers, aimed at managing respiratory diseases such as asthma. The company builds diagnostic sensor devices and targets clinicians, patients, and the in vitro diagnostics market.

4 investors